*Sponsored
Krypton Street Initiates Coverage On Avalon GloboCare Corp. (NASDAQ: ALBT) Starting This Morning—Thursday, June 26, 2025
Here's What We Can Tell You—Right Now…
Flying Under The Radar As (ALBT) Aligns With AI, Automation, And No-Code Infrastructure
Fewer Than 830K Shares In (ALBT)'s Public Float Create A Razor-Thin Structure Which Could Lead To The Potential For Significant Swings.
RSI Hovering In The Mid-30s Highlights The Potential For A Trend Reversal As (ALBT) Nears "Oversold Territory"
Proposed Merger Aligns (ALBT) With The AIaaS Sector Which Is Projected
To Grow Over 270% To Top $74B By 2029
Take A Look At (ALBT) While It's Still Early…
June 26, 2025 Thursday's Watchlist | We Have All Eyes On (ALBT) This Morning Dear Reader, Momentum is building—and (ALBT) opened above several key technical levels. (ALBT) kicked off the session at $3.69, above its 5-day ($3.05), 20-day ($3.24), and 50-day ($3.52) levels. With the 100-day up at $4.40, this one is staying locked on our screen today. This morning, a major update hit the wire. Avalon GloboCare Corp. (NASDAQ: ALBT) has signed a definitive agreement with Qi Diagnostics to co-develop a real-time can-na-bis breathalyzer—designed to help law enforcement and workplace safety teams detect potential impairment on the spot. It's a bold move—and it could put (ALBT) at the center of a sector projected to surge over 290%, from $4.48B in 2025 to $17.87B by 2034. (ALBT) tapped $4.18 in the early session today—an approximate 45% move off yesterday's $2.87 open. But this isn't a one-off headline—it's part of a broader shift. (ALBT) is quietly stepping into a new era of enterprise technology—where automation meets intelligence, and decision-making happens at machine speed. While many companies still toss around "AI" as a buzzword, Avalon is already pushing forward with execution—merging precision diagnostics, no-code software, and real-time automation into one future-ready blueprint. If you've ever used Dropbox, Slack, or Netflix, you've seen how SaaS transformed how we work. But AIaaS—Artificial Intelligence as a Service—is something else entirely. It doesn't just simplify tasks. It adapts, learns, and thinks—helping businesses operate smarter without needing massive IT teams. And the curve is rising fast: AIaaS is projected to grow more than 270%, from $20B in 2025 to $74B by 2029. 
This morning's news may just be the start of something much bigger. Keep reading to see why (ALBT) is now at the top of our watchlist.
(ALBT)'s proposed merger with YOOV Group could place it right in the middle of that growth curve—at a time when the market is starting to reward execution over experimentation. At the same time, technical indicators are flashing early signals. Across several timeframes, RSI levels have been hovering in the mid-30s—a zone that's historically seen setups form just before reversals. Based on recent readings: - 9-Day: 35.56%
- 14-Day: 35.38%
- 20-Day: 37.81%
These levels point toward (ALBT) potentially approaching "oversold territory", a pattern that has often preceded a reversal when matched with the right structural setup. And that setup may already be in place—because according to MarketWatch, (ALBT) has fewer than 830K shares in its public float. In situations like this, even small shifts in attention could lead to the potential for significant swings, as you can see in the (ALBT) chart below. 
(ALBT) isn't a company chasing a trend—it's one that's been building quietly for years. The company has real products, real distribution, and now, a tech-forward strategy that's syncing with where the market is headed. And if the pivot to AIaaS gains traction, the timing here could prove more important than most people realize. (ALBT)'s rise to this moment began with precision health tools. The company brought to market the KetoAir™ breathalyzer, a handheld device that measures acetone levels in exhaled breath—giving users real-time insights into their ketosis status. The device is registered with the U.S. FDA as a Class I medical device and pairs with AI-driven nutrition software designed to help users manage ketogenic diets. (ALBT) holds exclusive distributorship rights for the KetoAir across North America, South America, the EU, and the UK—targeting growing demand for smart health solutions. But the real inflection point? (ALBT)'s proposed merger with YOOV Group Holding Limited marks a high-conviction move into AI-powered business automation. YOOV operates a no-code platform designed to help companies digitize and streamline operations through integrated AI, workflow automation, and data systems—offering scalable solutions that require no technical expertise. The two companies have filed a joint Form S-4 with the U.S. Securities and Exchange Commission, outlining their intent to form a new AI automation entity listed under the ticker "YOOV." The transaction is expected to close in the third quarter of 2025, pending shareholder and Nasdaq approval. If approved, this would bring YOOV's accelerating revenue model—59.1% growth year-over-year—and positive net income under the (ALBT) umbrella. YOOV also brings with it a diversified model, operating through YOOV Capital Limited and YOOV Insurance Services Limited, which apply data analytics to financial services and insurance brokerage. This merger reflects more than just a strategic alignment—it's a platform buildout. By integrating (ALBT)'s background in precision diagnostics and global health distribution with YOOV's AIaaS engine, the combined entity aims to meet growing global demand for intelligent, automated infrastructure. The merger is still subject to shareholder and Nasdaq approval, but (ALBT)'s positioning within an AIaaS sector projected to grow over 270%—from $20B in 2025 to more than $74B by 2029—makes this transition worth serious attention. 
Momentum is building—fast. Technical indicators are lining up. And with this setup now moving out of the shadows, the window to take a closer look could be limited.
So For This Morning, Thursday, June 26, 2025 — Here's 7 Reasons Why
(ALBT) Is Topping Our Watchlist
1. Flying Under The Radar: while much of the market is still focused elsewhere, (ALBT) is building a platform that blends diagnostics, automation, and no-code AI for real-world use cases.
2. Ultra Low Float: with fewer than 830k shares listed in its public float, (ALBT) has a structure where modest attention can create oversized reactions. 3. Oversold Signal: recent RSI levels hovering in the mid-30s place (ALBT) near a zone that's historically aligned with potential trend reversals. 4. Sector Growth Acceleration: (ALBT)'s proposed merger aligns it with the fast-growing AIaaS sector, forecasted to expand over 270% to $74B by 2029. 5. FDA-Listed Product: (ALBT) introduced the KetoAir™ breathalyzer, registered as a Class I device, targeting a data-driven approach to metabolic health. 6. Global Reach: (ALBT) holds exclusive rights to distribute KetoAir™ across North America, South America, the EU, and the UK—regions seeing increased traction in smart health tools. 7. Merger Momentum: (ALBT) and YOOV Group filed a joint Form S-4 with the SEC, detailing plans to create a publicly listed AI automation company. Companies with this kind of setup don't stay overlooked for long. (ALBT) has built a multi-pronged story that's only now starting to surface—right as market conditions may be aligning. Take A Look At (ALBT) While It's Still Early…
Keep in mind, (ALBT) has fewer than 830K shares listed in its public float—meaning even small shifts in attention could lead to the potential for significant swings Add in RSI levels sitting near the mid-30s, and you've got a setup that's historically aligned with trend reversals. Now layer on a proposed merger targeting the AIaaS sector—projected to climb over 270% to $74B by 2029—and the timing gets even more critical. We're watching (ALBT) like a hawk right now. Take a look at (ALBT) while it's still early. (ALBT) tapped $4.18 in the early session today—an approximate 45% move off yesterday's $2.87 open. (ALBT) kicked off the session at $3.69, above its 5-day ($3.05), 20-day ($3.24), and 50-day ($3.52) levels. With the 100-day up at $4.40, this one is staying locked on our screen today. Make sure you're watching out for my next update. Sincerely, Alex Ramsay
Co-Founder / Managing Editor
Krypton Street Newsletter
| 
Tidak ada komentar:
Posting Komentar